Kaleido Biosciences is a biotechnology business based in the US. Kaleido Biosciences shares (KLDO) are listed on the PINK and all prices are listed in US Dollars. Kaleido Biosciences employs 76 staff and has a trailing 12-month revenue of around $1.1 million.
Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
| Latest market close | $0.00 |
|---|---|
| 52-week range | $0.00 - $0.00 |
| 50-day moving average | $0.00 |
| 200-day moving average | $0.00 |
| Wall St. target price | $22.00 |
| PE ratio | N/A |
| Dividend yield | N/A (0%) |
| Earnings per share (TTM) | $-2.16 |
Historical closes compared with the close of $0.0001 from 2024-09-04
| 1 week (2024-08-29) | 0.0001 |
|---|---|
| 1 month (2024-08-05) | 0.0001 |
| 3 months (2024-06-05) | 0.0001 |
| 6 months (2024-03-05) | 0.0001 |
| 1 year (2023-09-05) | 0.0001 |
|---|---|
| 2 years (2022-09-02) | -90.91% |
| 3 years (2021-09-03) | 6.36 |
| 5 years (2019-09-05) | 8.87 |
| Revenue TTM | $1.1 million |
|---|---|
| Gross profit TTM | $-66,699,000 |
| Return on assets TTM | -99.93% |
| Return on equity TTM | -580.57% |
| Profit margin | 0% |
| Book value | $0.25 |
| Market Capitalization | $4,262 |
TTM: trailing 12 months
We're not expecting Kaleido Biosciences to pay a dividend over the next 12 months.
Over the last 12 months, Kaleido Biosciences's shares have ranged in value from as little as $0 up to $0.0005. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (PINK average) beta is 1, while Kaleido Biosciences's is 36.45. This would suggest that Kaleido Biosciences's shares are significantly more volatile than the average for this exchange and represent a higher risk.
Kaleido Biosciences, Inc. , a clinical-stage healthcare company, develops microbiome metabolic therapies. The company develops KB195 for the treatment of patients with urea cycle disorder; KB295 to treat ulcerative colitis; KB174 for the treatment of hepatic encephalopathy; and KB109 to treat COVID-19 disease. It also develops programs for the treatment of multi drug resistant infection, chronic kidney disease, atherosclerotic cardiovascular disease, cardio-metabolic syndrome, immuno-oncology, and inflammatory bowel diseases. The company has collaboration agreements with Institute Gustave Roussy, Washington University, and Janssen. Kaleido Biosciences, Inc. was incorporated in 2015 and is headquartered in Lexington, Massachusetts.
Use this calculator to quickly see potential outcomes of your options trades.
Check out our picks of the best paper trading platforms to practice trading and investing with fake money.
These are the best day trading platforms, according to Finder’s comprehensive analysis.
Explore the best bonuses for opening a new brokerage account.
These are the best trading platforms for beginners, according to Finder’s comprehensive analysis.
Want to buy and sell international stocks? Here are the top brokers to help you trade global markets.
These are the best discount brokers of 2024 according to Finder’s comprehensive review.
See our picks of the best brokerage accounts, including Fidelity, SoFi, Charles Schwab, Public, Robinhood and E*TRADE .
What you need to know about investing in the leading indicator for the overall US stock market.
Check out the best-performing ETFs so far in 2024.